Spruce Biosciences, Inc. Common Stock (SPRB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Spruce Biosciences, Inc. Common Stock (SPRB) has a cash flow conversion efficiency ratio of -0.152x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.46 Million) by net assets ($42.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Spruce Biosciences, Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
Spruce Biosciences, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Spruce Biosciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Spruce Biosciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spruce Biosciences, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SKYX Platforms Corp
NASDAQ:SKYX
|
-0.252x |
|
Interactive Digital Technologies
TWO:6486
|
0.015x |
|
Paramita Bangun Sarana Tbk PT
JK:PBSA
|
0.083x |
|
Graphene Manufacturing Group Ltd
V:GMG
|
-0.208x |
|
Dynagas LNG Partners LP
NYSE:DLNG
|
0.054x |
|
SSH Communications Security Oyj
HE:SSH1V
|
-0.076x |
|
Sungei Bagan Rubber Malaya
KLSE:2569
|
0.004x |
|
PT Indonesia Kendaraan Terminal Tbk
JK:IPCC
|
0.066x |
Annual Cash Flow Conversion Efficiency for Spruce Biosciences, Inc. Common Stock (2018–2025)
The table below shows the annual cash flow conversion efficiency of Spruce Biosciences, Inc. Common Stock from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see SPRB market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $42.52 Million | $-33.33 Million | -0.784x | +59.63% |
| 2024-12-31 | $28.82 Million | $-55.96 Million | -1.942x | -346.47% |
| 2023-12-31 | $76.51 Million | $-33.27 Million | -0.435x | +28.54% |
| 2022-12-31 | $68.49 Million | $-41.68 Million | -0.609x | -88.94% |
| 2021-12-31 | $111.37 Million | $-35.88 Million | -0.322x | -74.92% |
| 2020-12-31 | $149.43 Million | $-27.52 Million | -0.184x | -144.72% |
| 2019-12-31 | $-30.64 Million | $-12.62 Million | 0.412x | -14.45% |
| 2018-12-31 | $-17.80 Million | $-8.57 Million | 0.481x | -- |
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating… Read more